Mimran A, Insua A, Ribstein J, Bringer J, Monnier L
Department of Medicine, Centre Hospitalier Universitaire, Montpellier, France.
Diabetes Care. 1988 Nov-Dec;11(10):850-3. doi: 10.2337/diacare.11.10.850.
In these studies, the effect of a 6-wk treatment by placebo, the calcium-channel blocker nifedipine, or the converting-enzyme inhibitor captopril was assessed in normotensive patients with insulin-dependent diabetes and incipient nephropathy. In response to captopril and nifedipine, arterial pressure decreased slightly and to a similar extent. These drugs resulted in opposite effects on urinary excretion of albumin [i.e., increase in urinary albumin excretion (UAE) by 40% during nifedipine treatment and decrease by 40% during captopril treatment]. No change in UAE was observed in the placebo group. This observation of opposite changes in UAE in the presence of a similar fall in arterial pressure suggests that the effects of captopril and nifedipine on UAE result from some difference in their intrarenal action. The data do not present recommendations for the use or disuse of captopril or nifedipine in such a group of patients and do not allow extrapolation to hypertensive diabetic subjects well controlled by other conventional antihypertensive agents.
在这些研究中,对胰岛素依赖型糖尿病且有早期肾病的血压正常患者,评估了安慰剂、钙通道阻滞剂硝苯地平或转化酶抑制剂卡托普利进行6周治疗的效果。硝苯地平和卡托普利治疗后,动脉压均有轻微下降,且下降程度相似。但这两种药物对尿白蛋白排泄产生了相反的影响[即硝苯地平治疗期间尿白蛋白排泄(UAE)增加40%,而卡托普利治疗期间减少40%]。安慰剂组的UAE未观察到变化。在动脉压出现相似下降的情况下,UAE却发生相反变化,这一观察结果表明,卡托普利和硝苯地平对UAE的影响源于它们肾内作用的某些差异。这些数据并未针对此类患者使用或停用卡托普利或硝苯地平提出建议,也无法外推至使用其他传统抗高血压药物控制良好的高血压糖尿病患者。